Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Want to cut your energy bills? Here’s how five experts are doing it 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
REDWOOD CITY, Calif., March 01, 2017 -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, will announce financial results on Wednesday, March 8, 2017. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review 2016 fourth quarter and full-year results and recent corporate events beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by dialing 1-855-420-0692 (domestic) and 1-484-756-4194 (international) using the conference ID#80803820. The webcast of the conference call will be accessible in the Investor Relations section of the OncoMed website: http://www.oncomed.com. A press release detailing fourth quarter and full year results will be posted to the OncoMed website shortly before the conference call.
The web broadcast of the conference call will be available for replay through May 31, 2017 via the OncoMed website. An audio replay of the conference call can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) utilizing the conference ID number listed above.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer’s growth, recurrence and metastases. Demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), anti-DLL4/VEGF bispecific (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), anti-RSPO3 (OMP-131R10) and anti-TIGIT (OMP-313M32) are part of the company’s strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). OncoMed is independently developing brontictuzumab (anti-Notch1, OMP-52M51) and GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research efforts. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
Contact: Michelle Corral Senior Director, Investor Relations and Corporate Communications OncoMed Pharmaceuticals [email protected] (650) 995-8373
